01873.HK
Viva Biotech Holdings
HKSE · Healthcare · Biotechnology · CN
HKD 1.25
−1.96%Year over year
Reported trailing growth
- Revenue
- +2.9%
- EBITDA
- -12.1%
- EBIT
- -15.1%
- EPS
- +0.9%
- Free cash flow
- +32.8%
- Operating cash flow
- +21.6%
Forward estimates
Based on analyst estimates
- Revenue
- -48.6%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -10.1%
- EBITDA
- -3.6%
- EBIT
- -10.5%
- Net income
- +31.4%
- EPS
- +14.9%
- Free cash flow
- -13.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026